Misha Kudryshev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.
Internal documents shed new light on Sarepta FDA decision, which top agency official says was ‘exceptional’
While he has repeatedly advocated for accelerated gene therapy approvals, the FDA’s top cell and gene therapy official Peter Marks said that the agency’s landmark